<DOC>
	<DOCNO>NCT02955615</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety ILT-101 ( human recombinant interleukin 2 ( IL-2 ) ) patient moderate severe systemic lupus erythematosus .</brief_summary>
	<brief_title>ILT-101 Patients With Active Moderate Severe Systemic Lupus Erythematosus ( SLE )</brief_title>
	<detailed_description>Interleukin 2 ( IL-2 ) play important role immune homeostasis act T lymphocyte . In systemic lupus erythematosus , call `` insufficiency '' subpopulation T lymphocytes , regulatory T cell ( Tregs ) lead alter immune balance regulatory effector T cell . These cell seem play major role physiopathology disease . Many research enlighten fact Tregs/Teffs balance restore administer low dose IL-2 . It thus assume treatment low dose IL-2 may impact positively progression disease thus help patient improve clinical outcome .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Confirmed diagnosis SLE Active SLE On stable background therapy 1 month Using highly effective contraception Serious organ failure ( renal functional impairment , severe central nervous system manifestation , severe heart failure , liver failure ) Any clinical evidence active chronic infection HIV , hepatitis B , hepatitis C Clinical significant pleuritis pericarditis Type1 Diabetes and/or CROHN 's disease Use Benlysta ( belimumab ) past 4 week Use Rituximab past 6 month Vaccination live attenuate virus last month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>